MCID: CHL152
MIFTS: 44

Childhood Acute Lymphocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Childhood Acute Lymphocytic Leukemia

MalaCards integrated aliases for Childhood Acute Lymphocytic Leukemia:

Name: Childhood Acute Lymphocytic Leukemia 12 52 15
Childhood Acute Lymphoblastic Leukemia 12 52 15
Pediatric Acute Lymphoblastic Leukemia 52
Childhood All 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0080144
NCIt 49 C3168

Summaries for Childhood Acute Lymphocytic Leukemia

NIH Rare Diseases : 52 Childhood acute lymphoblastic leukemia (ALL) is a type of cancer of the blood and bone marrow, and the most common type of cancer in children. In children with this condition, too many stem cells made by the bone marrow become lymphoblasts , B lymphocytes , or T lymphocytes . These cells do not function normally and have trouble fighting off infections. Signs and symptoms may include fever; easy bruising or bleeding; bone or joint pain; painless lumps in the neck, underarm, stomach, or groin; weakness; fatigue; and/or loss of appetite. Treatment depends on several factors and may include combination chemotherapy , targeted therapy , and/or stem cell transplant . On August 30 2017, Kymriah became the first gene therapy approved by the FDA. Kymriah is now an option for children and young adults up to 25 years old with B-Cell precursor ALL that has proven resistant to other treatments or has relapsed two or more times.

MalaCards based summary : Childhood Acute Lymphocytic Leukemia, also known as childhood acute lymphoblastic leukemia, is related to osteonecrosis and childhood leukemia. An important gene associated with Childhood Acute Lymphocytic Leukemia is LOC105377938 (Uncharacterized LOC105377938), and among its related pathways/superpathways are MicroRNAs in cancer and HIF-1-alpha transcription factor network. The drugs Thiotepa and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are digestive/alimentary and integument

Disease Ontology : 12 An acute lymphocytic leukemia occuring during childhood.

Related Diseases for Childhood Acute Lymphocytic Leukemia

Diseases related to Childhood Acute Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 31.3 VEGFA MTHFR ABCB1
2 childhood leukemia 30.5 PBX1 MTHFR ETV6 ARID5B ABCB1
3 lymphoma, non-hodgkin, familial 30.4 VEGFA MIR18A MCL1 ETV6 ABCB1
4 methotrexate toxicity 30.3 MTHFR ABCB1
5 mucositis 30.3 VEGFA MTHFR ABCB1
6 cerebral sinovenous thrombosis 30.3 MTHFR ASPG
7 leukemia, acute myeloid 30.3 VEGFA PBX1 MIR18A MCL1 ETV6 CEBPE
8 hematologic cancer 29.7 VEGFA NR3C1 MIRLET7F1 MIR18A MCL1 ETV6
9 leukemia, acute lymphoblastic 29.3 PBX1 NR3C1 MTHFR MIR18A MCL1 ETV6
10 b-cell childhood acute lymphoblastic leukemia 13.0
11 t-cell childhood acute lymphocytic leukemia 12.5
12 lymphocytic leukemia 11.0
13 leukemia 10.7
14 chromosomal triplication 10.6
15 splenomegaly 10.5
16 hemifacial spasm 10.5 VEGFA MTHFR
17 severe combined immunodeficiency 10.5
18 lipid metabolism disorder 10.5
19 idiopathic nephrotic syndrome 10.4 NR3C1 ABCB1
20 central nervous system disease 10.4
21 nervous system disease 10.4
22 retinoblastoma 10.4
23 graft-versus-host disease 10.4
24 lymphoma 10.4
25 testicular leukemia 10.4
26 familial retinoblastoma 10.4
27 differentiated thyroid carcinoma 10.4 VEGFA MTHFR ETV6
28 bone mineral density quantitative trait locus 3 10.4
29 acute t cell leukemia 10.4
30 neuropathy 10.4
31 47,xyy 10.4
32 acute graft versus host disease 10.4
33 soft tissue sarcoma 10.3 VEGFA ABCB1
34 leukemia, chronic lymphocytic 10.3
35 body mass index quantitative trait locus 1 10.3
36 lymphoblastic lymphoma 10.3
37 peripheral nervous system disease 10.3
38 branch retinal artery occlusion 10.3 VEGFA MTHFR
39 lymphoma, hodgkin, classic 10.3
40 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
41 body mass index quantitative trait locus 11 10.3
42 uterine benign neoplasm 10.3 VEGFA MIR18A CCNC
43 reproductive organ benign neoplasm 10.3 VEGFA MIR18A CCNC
44 wilms tumor 1 10.2
45 allergic rhinitis 10.2
46 pollen allergy 10.2
47 hyperparathyroidism 10.2
48 dermatitis 10.2
49 cranial nerve palsy 10.2
50 pneumonia 10.2

Graphical network of the top 20 diseases related to Childhood Acute Lymphocytic Leukemia:



Diseases related to Childhood Acute Lymphocytic Leukemia

Symptoms & Phenotypes for Childhood Acute Lymphocytic Leukemia

MGI Mouse Phenotypes related to Childhood Acute Lymphocytic Leukemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 ABCB1 ARID5B CEBPE ETV6 NR3C1 PBX1
2 integument MP:0010771 9.23 ASPG CEBPE ETV6 MCL1 MTHFR NR3C1

Drugs & Therapeutics for Childhood Acute Lymphocytic Leukemia

Drugs for Childhood Acute Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Oprelvekin Approved, Investigational Phase 4 145941-26-0
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Ethylene Phase 4 74-85-1 6325
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
7
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
8
Mercaptopurine Approved Phase 3 50-44-2 667490
9
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 6055-19-2, 50-18-0 2907
10
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
11
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
12
Calcium carbonate Approved, Investigational Phase 3 471-34-1
13
Sirolimus Approved, Investigational Phase 3 53123-88-9 5284616 6436030 46835353
14
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
15
Lenograstim Approved, Investigational Phase 3 135968-09-1
16
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
17
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
20
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
21
Acyclovir Approved Phase 3 59277-89-3 2022
22
Ondansetron Approved Phase 3 99614-02-5 4595
23
Tazobactam Approved Phase 3 89786-04-9 123630
24
Piperacillin Approved Phase 3 66258-76-2 43672
25
Vancomycin Approved Phase 3 1404-90-6 441141 14969
26
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
27
Captopril Approved Phase 3 62571-86-2 44093
28
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
29
Palivizumab Approved, Investigational Phase 3 188039-54-5
30
Ribavirin Approved Phase 3 36791-04-5 37542
31
Dasatinib Approved, Investigational Phase 2, Phase 3 302962-49-8 3062316
32
Ichthammol Approved Phase 2, Phase 3 8029-68-3
33
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
34
Etoposide Approved Phase 3 33419-42-0 36462
35
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
36
Mesna Approved, Investigational Phase 3 3375-50-6 598
37
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
38
Busulfan Approved, Investigational Phase 3 55-98-1 2478
39
Mycophenolic acid Approved Phase 3 24280-93-1 446541
40
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
42
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
43
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
44
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2, Phase 3 60-18-4 6057
46
Emodepside Investigational, Vet_approved Phase 2, Phase 3 155030-63-0
47
Cortisone Experimental Phase 3 53-06-5 222786
48 BB 1101 Phase 2, Phase 3
49 Alkylating Agents Phase 2, Phase 3
50 Immunologic Factors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 363)
# Name Status NCT ID Phase Drugs
1 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
2 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
3 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
4 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
5 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
6 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
7 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
8 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
9 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
10 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
11 TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS Unknown status NCT00002499 Phase 2, Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;dexamethasone;methotrexate;prednisone;vincristine sulfate
12 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
13 A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia Unknown status NCT00764907 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
14 Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial Unknown status NCT00003437 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate
15 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
16 Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial Completed NCT00186901 Phase 3 Calcium carbonate (Tums), vitamin D
17 Nordic Society of Paediatric Haematology and Oncology Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults (18-45 Years of Age) With ALL. Efficacy of Individualised 6MP Dosing During Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
18 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
19 EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY Completed NCT00002816 Phase 3 cytarabine;dexamethasone;etoposide;idarubicin;ifosfamide;leucovorin calcium;mesna;pegaspargase;therapeutic hydrocortisone;thioguanine;vincristine sulfate;Methotrexate
20 A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
21 A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
22 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
23 ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia Completed NCT00430118 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine
24 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion Completed NCT00819351 Phase 3 PEG Asparaginase at six weeks interval;PEG Asparaginase at two weeks interval
25 Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study Completed NCT00002812 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;idarubicin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
26 ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study Completed NCT00005585 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
27 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
28 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
29 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
30 ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study Completed NCT00005603 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate
31 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
32 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
33 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
34 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
35 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
36 Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00005945 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;thioguanine;vincristine sulfate
37 A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia Completed NCT01829711 Phase 3 Moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
38 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
39 Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia Completed NCT00002744 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisone;therapeutic hydrocortisone;thioguanine;vincristine sulfate
40 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
41 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
42 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
43 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
44 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
45 High Risk B-Precursor Acute Lymphoblastic Leukemia Completed NCT00075725 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine sulfate
46 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
47 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
48 International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia Completed NCT00015873 Phase 3 asparaginase;cytarabine;mercaptopurine;methotrexate;prednisolone;vincristine sulfate
49 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
50 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia Completed NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus

Search NIH Clinical Center for Childhood Acute Lymphocytic Leukemia

Genetic Tests for Childhood Acute Lymphocytic Leukemia

Anatomical Context for Childhood Acute Lymphocytic Leukemia

MalaCards organs/tissues related to Childhood Acute Lymphocytic Leukemia:

40
Bone, Bone Marrow, T Cells, B Cells, Myeloid, Brain, Testes

Publications for Childhood Acute Lymphocytic Leukemia

Articles related to Childhood Acute Lymphocytic Leukemia:

(show top 50) (show all 3431)
# Title Authors PMID Year
1
Paternal Smoking Before Conception and During Pregnancy Is Associated With an Increased Risk of Childhood Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis of 17 Case-Control Studies. 61
31743318 2020
2
miRNA deregulation in childhood acute lymphoblastic leukemia: a systematic review. 61
31833405 2020
3
Physical Activity and Sedentary Behaviors in Childhood Acute Lymphoblastic Leukemia Survivors. 61
31568179 2020
4
Poorer outcome of childhood acute lymphoblastic leukemia in the Bedouin population: A report from the Berlin-Frankfurt-Muenster-based Israeli national protocols. 61
31595664 2020
5
Dietary Intakes Are Associated with HDL-Cholesterol in Survivors of Childhood Acute Lymphoblastic Leukaemia. 61
31817482 2019
6
Time course of peripheral blood count recovery during induction chemotherapy for childhood acute lymphoblastic leukemia. 61
31126219 2019
7
MicroRNA as a prognostic biomarker for survival in childhood acute lymphoblastic leukemia: a systematic review. 61
31807971 2019
8
A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia. 61
30357334 2019
9
Impact of myosteatosis in survivors of childhood acute lymphoblastic leukemia. 61
31226904 2019
10
Childhood Acute Lymphoblastic Leukemia Survivors Have a Substantially Lower Cardiorespiratory Fitness Level Than Healthy Canadians Despite a Clinically Equivalent Level of Physical Activity. 61
31287753 2019
11
Early Recovery of Height Velocity in Prepubertal Children With Acute Lymphoblastic Leukemia Treated by a Short Intensive Phase Without Cranial Radiation Therapy. 61
31842181 2019
12
Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. 61
31657981 2019
13
In vitro knock-out of miR-155 suppresses leukemic and HCV virus loads in pediatric HCV-4-associated acute lymphoid leukemia: A promising target therapy. 61
31696995 2019
14
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity. 61
31765480 2019
15
TP53 alterations in relapsed childhood acute lymphoblastic leukemia. 61
31729120 2019
16
Untargeted adductomics of newborn dried blood spots identifies modifications to human serum albumin associated with childhood leukemia. 61
31760269 2019
17
Improved Outcomes of Childhood Acute Lymphoblastic Leukemia: A Retrospective Single Center Study in Saudi Arabia. 61
31759364 2019
18
Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. 61
31686588 2019
19
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia. 61
31725823 2019
20
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia-Reply. 61
31725836 2019
21
Association of Anesthesia Care and Cognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia. 61
31725852 2019
22
Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia. 61
31727091 2019
23
Evaluation of Sample Quality As Preanalytical Error in Flow Cytometry Analysis in Childhood Acute Lymphoblastic Leukemia. 61
31814813 2019
24
Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude lifetime cohort study. 61
31714590 2019
25
Improving survival outcomes of childhood acute lymphoblastic leukemia: A 25-year experience from a single center in Saudi Arabia. 61
31184419 2019
26
Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. 61
30923090 2019
27
Cranial Irradiation in Childhood Acute Lymphoblastic Leukemia Is Related to Subclinical Left Ventricular Dysfunction and Reduced Large Artery Compliance in Cancer Survivors. 61
31766118 2019
28
Secondhand smoke: A new and modifiable prognostic factor in childhood acute lymphoblastic leukemias. 61
31479979 2019
29
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells. 61
31789308 2019
30
Significance tests for analyzing gene expression data with small sample sizes. 61
30874796 2019
31
Visual short-term memory activation patterns in adult survivors of childhood acute lymphoblastic leukemia. 61
31310324 2019
32
DNA methylation and the hygiene hypothesis: connecting respiratory allergy and childhood acute lymphoblastic leukemia. 61
31536380 2019
33
ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. 61
31573954 2019
34
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. 61
31102422 2019
35
Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors. 61
31055782 2019
36
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. 61
31647152 2019
37
Prevention of Long-term Adverse Health Outcomes With Cardiorespiratory Fitness and Physical Activity in Childhood Acute Lymphoblastic Leukemia Survivors. 61
30688830 2019
38
Spatial-Temporal Cluster Analysis of Childhood Cancer in California. 61
31596791 2019
39
Central nervous system disease in childhood acute lymphoblastic leukemia. 61
26990196 2019
40
Prevalence of vitamin D deficiency in childhood acute lymphoblastic leukemia and its association with adverse outcomes during induction phase of treatment. 61
31635487 2019
41
Physical fitness and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime cohort. 61
31631333 2019
42
Prednisolone Prophase for a Week Versus Upfront Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia: An Analysis With Reference to Induction Mortality in a Developing Country. 61
31688627 2019
43
[Effects of MiR-221-Mediated Wnt/β- Catenin Signaling Pathway on Biological Activity of Childhood Acute Lymphoblastic Leukemia Cells]. 61
31607285 2019
44
Clinico-epidemiological features and response in childhood acute lymphoblastic leukemia at regional cancer center of Northeast India. 61
31807488 2019
45
Long-Term Risk of Hospitalization Among Five-Year Survivors of Childhood Leukemia in the Nordic Countries. 61
30753563 2019
46
Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting ETV6. 61
31519648 2019
47
ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis. 61
31111395 2019
48
Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors. 61
30778669 2019
49
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. 61
30655370 2019
50
Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. 61
31844443 2019

Variations for Childhood Acute Lymphocytic Leukemia

Copy number variations for Childhood Acute Lymphocytic Leukemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 250737 9 21967751 21994490 Deletion CDKN2A pediatric acute lymphoblastic leukemia

Expression for Childhood Acute Lymphocytic Leukemia

Search GEO for disease gene expression data for Childhood Acute Lymphocytic Leukemia.

Pathways for Childhood Acute Lymphocytic Leukemia

Pathways related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 VEGFA MIRLET7F1 MIR18A MCL1 ABCB1
2 10.94 VEGFA MCL1 ABCB1
3 10.5 MCL1 ETV6

GO Terms for Childhood Acute Lymphocytic Leukemia

Biological processes related to Childhood Acute Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.63 VEGFA PBX1 NR3C1 ETV6 CEBPE CCNC
2 adrenal gland development GO:0030325 8.96 PBX1 ARID5B
3 macrophage differentiation GO:0030225 8.62 VEGFA CEBPE

Sources for Childhood Acute Lymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....